Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Berenson Cancer Center, West Hollywood, California, United States
Contact: Study coordinator (Regina Swift, RN) · rswift@berensoncancercenter.com · 310-623-1222
Contact: Study coordinator (Marceya Soto) · msoto@berensoncancercenter.com · 310-623-1222
Contact: Study coordinator (James Berenson, MD)

Study leads

James Berenson, MD
Principal Investigator
Oncotherapeutics

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma · Cancer

Abroad (travel likely)RecruitingPHASE2

Chapel Hill, United States · Charlotte, United States

A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Parkville, Australia

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Iowa City, United States

Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma (RRMM)

Abroad (travel likely)RecruitingPHASE1

Boston, United States · Boston, United States